172 related articles for article (PubMed ID: 36329368)
1. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
[TBL] [Abstract][Full Text] [Related]
2. Loss of H3K27me3 in meningiomas.
Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
[TBL] [Abstract][Full Text] [Related]
3. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
4. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
[TBL] [Abstract][Full Text] [Related]
5. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
7. Loss of H3K27me3 in WHO grade 3 meningioma.
Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
11. Is Falcine Meningioma a Diffuse Disease of the Falx? Case Series and Analysis of a "Grade Zero" Resection.
Mooney MA; Abolfotoh M; Bi WL; Tavanaiepour D; Almefty RO; Bassiouni H; Pravdenkova S; Dunn IF; Al-Mefty O
Neurosurgery; 2020 Oct; 87(5):900-909. PubMed ID: 32294205
[TBL] [Abstract][Full Text] [Related]
12. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
[TBL] [Abstract][Full Text] [Related]
14. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of multimodality management for parasagittal meningiomas.
Hua L; Wang D; Zhu H; Deng J; Luan S; Chen H; Sun S; Tang H; Xie Q; Wakimoto H; Gong Y
J Neurooncol; 2020 Apr; 147(2):441-450. PubMed ID: 32088814
[TBL] [Abstract][Full Text] [Related]
16. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
17. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
20. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
